NCT04328844 2026-03-30A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic CancersiOncturaPhase 1 Active not recruiting210 enrolled
NCT02712905 2025-11-04An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced MalignanciesIncyte CorporationPhase 1/2 Terminated116 enrolled 36 charts
NCT02711137 2025-10-21Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced MalignanciesIncyte CorporationPhase 1/2 Terminated137 enrolled 31 charts
NCT02431260 2019-06-14An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced MalignanciesIncyte CorporationPhase 1/2 Terminated69 enrolled 34 charts
NCT00154388 2016-11-18Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare DiseasesNovartisPhase 2 Completed185 enrolled
NCT00538850 2014-03-05Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer PainINSYS Therapeutics IncPhase 3 Completed130 enrolled 9 charts